Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis.

[1]  A. Dick,et al.  Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy , 2017, Pediatric Rheumatology.

[2]  A. Denniston,et al.  A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. , 2017, Health technology assessment.

[3]  Ashley P Jones,et al.  Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis , 2017, The New England journal of medicine.

[4]  J. Shepherd,et al.  The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. , 2016, Health technology assessment.

[5]  K. Eames,et al.  Measuring Health Utilities in Children and Adolescents: A Systematic Review of the Literature , 2015, PloS one.

[6]  J. Brazier,et al.  Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. , 2014, Health technology assessment.

[7]  Ashley P Jones,et al.  A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial) , 2014, Trials.

[8]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. , 2013, BMJ.

[9]  R. Edwards,et al.  EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[11]  Dmitri A. Jdanov,et al.  Human Mortality Database , 2019, Encyclopedia of Gerontology and Population Aging.

[12]  R. Rosenfeld,et al.  Authority , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[13]  Jeremy B Sussman,et al.  An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials , 2010, BMJ : British Medical Journal.

[14]  A. Dick,et al.  Non-Infectious Pediatric Uveitis , 2009, Paediatric drugs.

[15]  K. Minden,et al.  Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. , 2008, The New England journal of medicine.

[16]  L. Curtis,et al.  Unit Costs of Health and Social Care 2016 , 2015 .

[17]  R. Saurenmann,et al.  Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. , 2007, Arthritis and rheumatism.

[18]  I. Foeldvari,et al.  Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. , 2005, The Journal of rheumatology.

[19]  W. Christen,et al.  Outcomes of Treatment with Immunomodulatory Therapy in Patients with Corticosteroid-Resistant Juvenile Idiopathic Arthritis-Associated Chronic Iridocyclitis , 2005, Ocular immunology and inflammation.

[20]  D. Quinton,et al.  Unit Costs of Health and Social Care 2004 , 2004 .

[21]  M. Boyle,et al.  Multiattribute and Single‐Attribute Utility Functions for the Health Utilities Index Mark 3 System , 2002, Medical care.

[22]  H. Kautiainen,et al.  Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. , 2001, Ophthalmology.

[23]  A. Weiss,et al.  Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. , 1998, The Journal of pediatrics.